Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays
Background: Patients with severe hemophilia A and inhibitors are at risk of bleeding during invasive procedures. The standard of care for preventing perioperative bleeding has been replacement therapy with FVIII concentrates or for patients with high-titer inhibitors, bypassing agents. However, ther...
| Váldodahkkit: | , , , , , |
|---|---|
| Materiálatiipa: | Artihkal |
| Giella: | English |
| Almmustuhtton: |
SAGE Publishing
2019-06-01
|
| Ráidu: | Therapeutic Advances in Hematology |
| Liŋkkat: | https://doi.org/10.1177/2040620719860025 |